Gut microbiota in non-hospitalised SARS-CoV-2 infection is compositionally distinct from IBS despite comparable dysbiosis prevalence: a prospective cohort study from acute infection to six months

Background Gut dysbiosis has been documented after COVID-19, but whether it occurs and persists after mild to moderate non-hospitalised infection, and how it compares with irritable bowel syndrome (IBS), remains unclear. Methods We prospectively followed 31 non-hospitalised patients with mild-to-moderate SARS-CoV-2 infection at acute infection, four weeks and six months using the GA-map® Dysbiosis Test, with healthy controls (n = 36) and patients with moderate-to-severe IBS (n = 58) as cross-sectional reference groups. Composition was compared by PERMANOVA on Bray-Curtis dissimilarities, individual taxa by Wilcoxon rank-sum tests with false discovery rate (FDR) correction, and within-patient change by linear mixed-effects models. Gastrointestinal symptoms, fatigue and cognitive symptoms were related to the microbiota by Spearman correlation. Results Overall composition differed across groups (p = 0.001). SARS-CoV-2 patients differed from healthy controls (adjusted p = 0.048, 0.005 and 0.007) and from IBS (adjusted p = 0.011, 0.004 and 0.004) at all three time points, whereas composition within the SARS-CoV-2 cohort did not change over follow-up and IBS did not differ from healthy controls. Alpha diversity did not differ across groups. Five taxa were altered at every time point against both reference groups, with Eubacterium rectale , Bacteroides stercoris , Ruminococcus gnavus and Proteobacteria depleted and Shigella spp. & Escherichia spp. elevated. Actinobacteria and Bifidobacterium spp. increased within patients by four weeks (both FDR = 0.002) and exceeded IBS levels at six months (both FDR < 0.001). Dysbiosis was as prevalent as in IBS (8/28, 3/29 and 7/26 versus 15/58) and more prevalent than in healthy controls (2/36) at baseline and six months, but individual trajectories were bidirectional and no patient was dysbiotic throughout. Gastrointestinal symptoms largely resolved, whereas mental fatigue remained at the IBS level and cognitive symptoms were present in 13/26 patients at six months versus 6/35 healthy controls. Neither individual taxa nor the Dysbiosis Index was associated with symptom severity in the SARS-CoV-2 cohort. Conclusions Gut microbiota alterations after mild-to-moderate SARS-CoV-2 infection persisted through six months without resembling the microbiota seen in IBS, and were not associated with persistent fatigue or cognitive symptoms. Corresponding author : [email protected]

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11478894/v1
Primary Topic
Gut microbiota and health
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Gut microbiota in non-hospitalised SARS-CoV-2 infection is compositionally distinct from IBS despite comparable dysbiosis prevalence: a prospective cohort study from acute infection to six months

Birgitte Berentsen, Astri Johansen Lundervold, Rebecca Jane Cox, Ingeborg Brønstad et al.
Research Square
Gut microbiota and health
preprint

Gut microbiota in non-hospitalised SARS-CoV-2 infection is compositionally distinct from IBS despite comparable dysbiosis prevalence: a prospective cohort study from acute infection to six months

Birgitte Berentsen, Astri Johansen Lundervold, Rebecca Jane Cox, Ingeborg Brønstad, Nina Langeland, Eline MR Hillestad
preprint en

Abstract

Background Gut dysbiosis has been documented after COVID-19, but whether it occurs and persists after mild to moderate non-hospitalised infection, and how it compares with irritable bowel syndrome (IBS), remains unclear. Methods We prospectively followed 31 non-hospitalised patients with mild-to-moderate SARS-CoV-2 infection at acute infection, four weeks and six months using the GA-map® Dysbiosis Test, with healthy controls (n = 36) and patients with moderate-to-severe IBS (n = 58) as cross-sectional reference groups. Composition was compared by PERMANOVA on Bray-Curtis dissimilarities, individual taxa by Wilcoxon rank-sum tests with false discovery rate (FDR) correction, and within-patient change by linear mixed-effects models. Gastrointestinal symptoms, fatigue and cognitive symptoms were related to the microbiota by Spearman correlation. Results Overall composition differed across groups (p = 0.001). SARS-CoV-2 patients differed from healthy controls (adjusted p = 0.048, 0.005 and 0.007) and from IBS (adjusted p = 0.011, 0.004 and 0.004) at all three time points, whereas composition within the SARS-CoV-2 cohort did not change over follow-up and IBS did not differ from healthy controls. Alpha diversity did not differ across groups. Five taxa were altered at every time point against both reference groups, with Eubacterium rectale , Bacteroides stercoris , Ruminococcus gnavus and Proteobacteria depleted and Shigella spp. & Escherichia spp. elevated. Actinobacteria and Bifidobacterium spp. increased within patients by four weeks (both FDR = 0.002) and exceeded IBS levels at six months (both FDR < 0.001). Dysbiosis was as prevalent as in IBS (8/28, 3/29 and 7/26 versus 15/58) and more prevalent than in healthy controls (2/36) at baseline and six months, but individual trajectories were bidirectional and no patient was dysbiotic throughout. Gastrointestinal symptoms largely resolved, whereas mental fatigue remained at the IBS level and cognitive symptoms were present in 13/26 patients at six months versus 6/35 healthy controls. Neither individual taxa nor the Dysbiosis Index was associated with symptom severity in the SARS-CoV-2 cohort. Conclusions Gut microbiota alterations after mild-to-moderate SARS-CoV-2 infection persisted through six months without resembling the microbiota seen in IBS, and were not associated with persistent fatigue or cognitive symptoms. Corresponding author : [email protected]

Research Square
Haukeland University Hospital (NO), University of Bergen (NO)
Helse- og Omsorgsdepartementet, Helse Vest, Haukeland Universitetssjukehus
Good health and well-being
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon